von Hippel-Lindau Disease
"von Hippel-Lindau Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.
| Descriptor ID |
D006623
|
| MeSH Number(s) |
C10.562.925 C14.907.077.925
|
| Concept/Terms |
von Hippel-Lindau Disease- von Hippel-Lindau Disease
- von Hippel Lindau Disease
- Familial Cerebello-Retinal Angiomatosis
- Angiomatoses, Familial Cerebello-Retinal
- Angiomatosis, Familial Cerebello-Retinal
- Cerebello-Retinal Angiomatoses, Familial
- Cerebello-Retinal Angiomatosis, Familial
- Familial Cerebello Retinal Angiomatosis
- Familial Cerebello-Retinal Angiomatoses
- Hippel-Lindau Disease
- Hippel Lindau Disease
- Lindau Disease
- von Hippel-Lindau Syndrome
- Syndrome, von Hippel-Lindau
- von Hippel Lindau Syndrome
- Angiomatosis Retinae
- Retinae, Angiomatosis
- VHL Syndrome
- Syndrome, VHL
- Syndromes, VHL
- VHL Syndromes
- Cerebelloretinal Angiomatosis, Familial
- Angiomatoses, Familial Cerebelloretinal
- Angiomatosis, Familial Cerebelloretinal
- Cerebelloretinal Angiomatoses, Familial
- Familial Cerebelloretinal Angiomatoses
- Familial Cerebelloretinal Angiomatosis
- Lindau's Disease
- Lindau's Diseases
- Lindaus Disease
|
Below are MeSH descriptors whose meaning is more general than "von Hippel-Lindau Disease".
Below are MeSH descriptors whose meaning is more specific than "von Hippel-Lindau Disease".
This graph shows the total number of publications written about "von Hippel-Lindau Disease" by people in this website by year, and whether "von Hippel-Lindau Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 3 | 0 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 3 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 4 | 0 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 2 | 4 |
| 2022 | 3 | 0 | 3 |
| 2023 | 3 | 0 | 3 |
| 2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "von Hippel-Lindau Disease" by people in Profiles.
-
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024 Oct; 25(10):1325-1336.
-
Oral Hypoxia-Inducible Factor 2a Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study. Ophthalmology. 2024 Nov; 131(11):1324-1332.
-
A Cerebellar Tumor-to-Tumor Metastasis in a Patient With Von Hippel-Lindau Disease. Appl Immunohistochem Mol Morphol. 2024 May-Jun 01; 32(5):244-248.
-
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clin Cancer Res. 2024 May 01; 30(9):1750-1757.
-
Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet J Rare Dis. 2024 Feb 16; 19(1):73.
-
Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease. Ophthalmology. 2024 May; 131(5):622-633.
-
Neurocutaneous Disorders in Pregnancy. Obstet Gynecol Surv. 2023 Oct; 78(10):606-619.
-
Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 10 01; 129(19):2927-2940.
-
Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. Clin Genitourin Cancer. 2023 04; 21(2):238-247.
-
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-17.